Clearmind Drugs continues to conduct section I-enabling preclinical scientific studies on its guide drug candidates. The main synthesis and elucidation on the framework on the copyright molecule was by Richard Willstätter in 1898. The company anticipates initiating Phase II scientific trials while in the near foreseeable future. Eleusis can